Halotestin Tablets 5mg/tab 50 Tabletten by Genesis

Usage

1. Verify the tablet marking and batch documentation prior to use — confirm HPLC-certified potency aligns with the declared 5 mg per tablet on the packaging.
2. Divide your daily dose into two equal administrations spaced approximately 10–12 hours apart, reflecting the fluoxymesterone half-life of roughly 9–10 hours to maintain sustained AR occupancy.
3. Swallow tablets whole with a full glass of water; do not crush or dissolve, as the 17α-methyl group's stability is optimised in the intact compressed tablet matrix.
4. Administer doses with or immediately after food to support gastric tolerability and modulate peak plasma concentration rise-rate, reducing the likelihood of acute androgenic receptor over-stimulation symptoms.
5. Log each dose against a daily tracker and schedule ALT/AST hepatic enzyme blood panels at baseline, mid-cycle, and post-cycle — the 17α-alkylation pathway places a defined burden on hepatic CYP metabolism that requires active monitoring.
6. Initiate PCT (e.g., Clomiphene or Tamoxifen) no later than 24–48 hours after the final tablet, consistent with the compound's documented clearance kinetics, to restore endogenous androgen axis function promptly.

Warnings

Frequently asked questions

How does fluoxymesterone bind to the androgen receptor compared to testosterone?

Fluoxymesterone binds the androgen receptor with a relative binding affinity estimated at approximately 1,940 % of the methyltrienolone reference standard — substantially exceeding testosterone's AR affinity. This is attributable to its 9α-fluoro and 11β-hydroxy substitutions, which optimise the molecule's three-dimensional fit within the AR ligand-binding domain, producing a stronger and more sustained transcriptional activation signal per unit dose.

What does fluoxymesterone's DHT-derivative chemical lineage mean for its physiological effects?

Being a DHT-derived compound, fluoxymesterone cannot be converted to oestrogen by the CYP19A1 aromatase enzyme. This means all receptor-mediated effects — erythropoietic stimulation, neuromuscular drive, myofibrillar protein transcription — occur without a concurrent oestrogen rise, making the androgenic activity 'clean' in the hormonal sense. The 17α-methyl group further distinguishes it from parent DHT by granting oral bioavailability through hepatic first-pass resistance.

Why does fluoxymesterone's androgen receptor affinity differ so significantly from other oral androgens?

The combination of three structural modifications — the electron-withdrawing 9-fluoro group, the 11β-hydroxyl, and the 17α-methyl — creates a molecular geometry that fits the AR ligand-binding pocket with exceptional complementarity. Each modification contributes independently: the fluoro group stabilises the A-ring conformation, the hydroxyl adds a hydrogen-bonding contact point, and the methyl group prevents rapid hepatic clearance, collectively producing a receptor interaction profile that is rare among clinically documented oral androgens.

Why is the 5 mg tablet strength a practical advantage for precise androgen receptor dosing protocols?

At 5 mg per tablet — the lowest single-unit strength in the fluoxymesterone format — users can titrate their androgen receptor exposure in discrete 5 mg increments without splitting tablets or approximating doses. This granularity is particularly relevant given fluoxymesterone's steep dose-response curve at the receptor level; small dose adjustments produce measurably different AR saturation outcomes, making the 5 mg unit a pharmacologically meaningful increment rather than an arbitrary convenience.

How are Genesis Halotestin 5 mg tablets verified for accurate fluoxymesterone content?

Each batch of Genesis Halotestin 5 mg tablets undergoes HPLC quantification referenced against a certified fluoxymesterone primary standard, confirming that per-tablet API content meets declared potency within validated acceptance criteria. An LAL (Limulus Amebocyte Lysate) endotoxin test is conducted on finished batches, and the entire manufacturing process runs within GMP-certified production suites subject to ongoing environmental monitoring. (2) angle_used

Manufacturer

Genesis enters the fluoxymesterone category with a manufacturing posture shaped entirely by the compound's pharmacological specificity: because fluoxymesterone exerts its effects through androgen receptor binding at sub-milligram-per-kilogram concentrations, tablet-to-tablet dose uniformity is not a convenience feature but a pharmacodynamic requirement. A ±10 % deviation in API content at the 5 mg dose level represents a full 0.5 mg swing — sufficient to shift receptor occupancy in a clinically meaningful direction. To address this, Genesis subjects the incoming fluoxymesterone API to identity confirmation and quantitative purity assessment before the material is authorised to enter the compression stage; a separate finished-tablet HPLC assay — run against a certified fluoxymesterone reference standard — provides the second, independent potency confirmation required for batch release. The 50-tablet oral solid format is packaged within a format validated for stability under recommended storage conditions, protecting the 17α-methyl group's structural integrity across the product's declared shelf-life. Genesis's broader oral androgen portfolio — spanning 17α-alkylated compounds across multiple strength categories — means the quality infrastructure supporting this fluoxymesterone line benefits from accumulated process knowledge specific to alkylated steroid compression, rather than being purpose-built for a single product.